- Home
- DYN vs CSAN Comparison
DYN vs CSAN Comparison
Compare DYN & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- CSAN
- Stock Information
- Founded
- DYN 1984
- CSAN 1936
- Country
- DYN United States
- CSAN Brazil
- Employees
- DYN N/A
- CSAN N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- CSAN Retail-Auto Dealers and Gas Stations
- Sector
- DYN Health Care
- CSAN Consumer Discretionary
- Exchange
- DYN Nasdaq
- CSAN Nasdaq
- Market Cap
- DYN 2.6B
- CSAN 2.6B
- IPO Year
- DYN 2020
- CSAN N/A
- Fundamental
- Price
- DYN $9.23
- CSAN $5.23
- Analyst Decision
- DYN Strong Buy
- CSAN Strong Buy
- Analyst Count
- DYN 12
- CSAN 1
- Target Price
- DYN $47.73
- CSAN $19.00
- AVG Volume (30 Days)
- DYN 1.8M
- CSAN 932.9K
- Earning Date
- DYN 05-01-2025
- CSAN 05-27-2025
- Dividend Yield
- DYN N/A
- CSAN 6.61%
- EPS Growth
- DYN N/A
- CSAN N/A
- EPS
- DYN N/A
- CSAN N/A
- Revenue
- DYN N/A
- CSAN $7,106,136,253.00
- Revenue This Year
- DYN N/A
- CSAN $294.00
- Revenue Next Year
- DYN N/A
- CSAN $3.87
- P/E Ratio
- DYN N/A
- CSAN N/A
- Revenue Growth
- DYN N/A
- CSAN 11.36
- 52 Week Low
- DYN $9.17
- CSAN $4.54
- 52 Week High
- DYN $47.45
- CSAN $12.77
- Technical
- Relative Strength Index (RSI)
- DYN 26.62
- CSAN 48.77
- Support Level
- DYN $10.72
- CSAN $5.33
- Resistance Level
- DYN $12.00
- CSAN $5.56
- Average True Range (ATR)
- DYN 0.76
- CSAN 0.17
- MACD
- DYN -0.11
- CSAN -0.00
- Stochastic Oscillator
- DYN 1.52
- CSAN 47.37
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.